Table 8. Antimicrobial drug treatment for children infected with Mycoplasma pneumoniae, Ohio, USA, 2015–2019*.
| Characteristic | MRMp, n = 12 | MSMp, n = 332 | p value |
|---|---|---|---|
| Patients with previous antimicrobial drug treatment, no. (%) | 5 (42) | 106 (32) | 0.5339 |
| Nonmacrolide | 5 (42) | 102 (31) | 0.5262 |
| Macrolide |
3 (25) |
7 (2.1) |
0.0017
|
| Definitive treatment during medical encounter, no. (%) | |||
| Azithromycin | 9 (75) | 317 (95.5) | 0.0197 |
| Levofloxacin | 3 (25) | 15 (4.5) | 0.0267 |
*Bold type indicates statistical significance. MRMp, macrolide-resistant Mycoplasma pneumoniae; MSMp, macrolide-sensitive Mycoplasma pneumoniae.